Net Income (Loss) Attributable to Parent in USD of Transcode Therapeutics, Inc. from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Transcode Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2020 to Q3 2025.
  • Transcode Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$4.86M, a 109% decline year-over-year.
  • Transcode Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$27.1M, a 81.8% decline year-over-year.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$16.8M, a 9.66% increase from 2023.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$18.5M, a 5.59% decline from 2022.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$17.6M, a 157% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Transcode Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$27.1M -$4.86M -$2.53M -109% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$24.6M -$4.28M +$914K +17.6% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$25.5M -$12.1M -$8.76M -263% 01 Jan 2025 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 -$16.8M -$5.92M -$1.83M -44.7% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$14.9M -$2.32M +$2.98M +56.2% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$17.9M -$5.19M -$849K -19.6% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 -$17.1M -$3.33M +$1.49M +30.9% 01 Jan 2024 31 Mar 2024 10-Q 14 Nov 2025
Q4 2023 -$18.5M -$4.09M +$1.05M +20.4% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$19.6M -$5.3M -$1.01M -23.6% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$18.6M -$4.34M +$330K +7.06% 01 Apr 2023 30 Jun 2023 10-Q 14 Nov 2024
Q1 2023 -$18.9M -$4.82M -$1.35M -38.8% 01 Jan 2023 31 Mar 2023 10-Q 14 Nov 2024
Q4 2022 -$17.6M -$5.13M -$2.33M -83.4% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024
Q3 2022 -$15.2M -$4.29M -$1.96M -84.1% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$13.3M -$4.67M -$7.44M -269% 01 Apr 2022 30 Jun 2022 10-Q 14 Nov 2023
Q1 2022 -$5.83M -$3.47M +$1.02M +22.6% 01 Jan 2022 31 Mar 2022 10-Q 14 Nov 2023
Q4 2021 -$6.84M -$2.8M -$2M -249% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$4.85M -$2.33M -$956K -69.6% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$3.89M $2.77M +$2.9M 01 Apr 2021 30 Jun 2021 10-Q 14 Nov 2022
Q1 2021 -$6.79M -$4.49M -$4.44M -10771% 01 Jan 2021 31 Mar 2021 10-Q 14 Nov 2022
Q4 2020 -$2.34M -$802K 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022
Q3 2020 -$1.37M 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$127K 01 Apr 2020 30 Jun 2020 10-Q 15 Nov 2021
Q1 2020 -$41.3K 01 Jan 2020 31 Mar 2020 10-Q 15 Nov 2021

Transcode Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$16.8M +$1.79M +9.66% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$18.5M -$981K -5.59% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 -$17.6M -$10.7M -157% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024
2021 -$6.84M -$4.5M -192% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$2.34M 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.